Core Viewpoint - The company reported a revenue of 934 million yuan for the fiscal year 2025, representing a year-on-year growth of 25.64%, while net profit showed a loss of 336 million yuan compared to a loss of 510 million yuan in the same period last year [1] Group 1 - The company actively expanded its market during the reporting period [1] - Sales of Adalimumab injection (Geleli) and Tocilizumab injection (Shilili) steadily increased compared to the same period last year [1] - The company launched Ustekinumab injection (STARJEMZA) in the United States, leading to growth in licensing income and sales revenue [1]

Core Viewpoint - Baotai (688177) is expected to reduce its losses in 2025, projecting a net profit attributable to shareholders of between -280 million to -390 million yuan, a decrease in losses of 120 million to 230 million yuan compared to the previous year [1] Financial Performance - The company anticipates revenue between 900 million to 970 million yuan, an increase of 157 million to 227 million yuan compared to the same period last year [1] - The sales of Adalimumab injection (Geleli) and Tocilizumab injection (Shilili) have steadily increased compared to the previous year [1] Market Expansion - The launch of Ustekinumab injection (STARJEMZA) in the United States has contributed to growth in both licensing income and sales revenue [1]